AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sarecycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 5298 | 1035654-66-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of sarecycline in treating acne vulgaris is not known.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 14 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK | 58 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK4,CDK9,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,STK33,SYK,TEK,TGFBR1 | 16 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | Moderate | 0.75 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 1, 2018 | FDA | ALLERGAN INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01AA14 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D003879 | Dermatologic Agents |
| FDA CS | M0021223 | Tetracyclines |
| FDA EPC | N0000175882 | Tetracycline-class Drug |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
Related Drugs by ATC class:
J01AA Tetracyclines 13 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acne vulgaris | indication | 88616000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.13 | acidic |
| pKa2 | 8.56 | acidic |
| pKa3 | 10.08 | acidic |
| pKa4 | 11.96 | acidic |
| pKa5 | 13.08 | acidic |
| pKa6 | 9.41 | Basic |
| pKa7 | 2.23 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 100MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9481639 | Aug. 10, 2028 | A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES |
| EQ 150MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9481639 | Aug. 10, 2028 | A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES |
| EQ 60MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9481639 | Aug. 10, 2028 | A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES |
| EQ 100MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 8513223 | Dec. 7, 2029 | A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE |
| EQ 150MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 8513223 | Dec. 7, 2029 | A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE |
| EQ 60MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 8513223 | Dec. 7, 2029 | A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE |
| EQ 100MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 8318706 | Jan. 3, 2032 | A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE |
| EQ 150MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 8318706 | Jan. 3, 2032 | A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE |
| EQ 60MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 8318706 | Jan. 3, 2032 | A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE |
| EQ 100MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9255068 | Feb. 9, 2033 | A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT |
| EQ 100MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9255068 | Feb. 9, 2033 | A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT |
| EQ 150MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9255068 | Feb. 9, 2033 | A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT |
| EQ 150MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9255068 | Feb. 9, 2033 | A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT |
| EQ 60MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9255068 | Feb. 9, 2033 | A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT |
| EQ 60MG BASE | SEYSARA | ALMIRALL | N209521 | Oct. 1, 2018 | RX | TABLET | ORAL | 9255068 | Feb. 9, 2033 | A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 94O110CX2E | UNII |
| 1035979-44-2 | SECONDARY_CAS_RN |
| 4038062 | VANDF |
| C4519292 | UMLSCUI |
| CHEBI:754990 | CHEBI |
| V7A | PDB_CHEM_ID |
| CHEMBL2364632 | ChEMBL_ID |
| 54681908 | PUBCHEM_CID |
| DB12035 | DRUGBANK_ID |
| CHEMBL2364633 | ChEMBL_ID |
| D10666 | KEGG_DRUG |
| 9743 | INN_ID |
| C000629276 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12921 | IUPHAR_LIGAND_ID |
| 781643008 | SNOMEDCT_US |
| 781650007 | SNOMEDCT_US |
| 294179 | MMSL |
| 35296 | MMSL |
| d09003 | MMSL |
| 017779 | NDDF |
| 017780 | NDDF |
| 2059018 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Seysara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-245 | TABLET, COATED | 60 mg | ORAL | NDA | 29 sections |
| Seysara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-246 | TABLET, COATED | 100 mg | ORAL | NDA | 29 sections |
| Seysara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16110-247 | TABLET, COATED | 150 mg | ORAL | NDA | 29 sections |